Dual BACH1 regulation by complementary SCF-type E3 ligases
Cell · 2024-12 · 187 (26) · 7585-7602.e25
DOI: 10.1016/j.cell.2024.11.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2024-12. Verfasst von Benedikt Goretzki und 25 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Sciences, Novartis Biomedical Research, Basel, Switzerland. Electronic address: bengoretzki@isomorphiclabs.com. Hauptthemen laut MEDLINE: Basic-Leucine Zipper Transcription Factors, Oxidative Stress. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Broad-complex, tramtrack, and bric-à-brac domain (BTB) and CNC homolog 1 (BACH1) is a key regulator of the cellular oxidative stress response and an oncogene that undergoes tight post-translational control by two distinct F-box ubiquitin ligases, SCFFBXO22 and SCFFBXL17. However, how both ligases recognize BACH1 under oxidative stress is unclear. In our study, we elucidate the mechanism by which FBXO22 recognizes a quaternary degron in a domain-swapped β-sheet of the BACH1 BTB dimer. Cancer-associated mutations and cysteine modifications destabilize the degron and impair FBXO22 binding but simultaneously expose an otherwise shielded degron in the dimer interface, allowing FBXL17 to recognize BACH1 as a monomer. These findings shed light on a ligase switch mechanism that enables post-translational regulation of BACH1 by complementary ligases depending on the stability of its BTB domain. Our results provide mechanistic insights into the oxidative stress response and may spur therapeutic approaches for targeting oxidative stress-related disorders and cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discovery Sciences, Novartis Biomedical Research, Basel, Switzerland. Electronic address: bengoretzki@isomorphiclabs.com.
- Discovery Sciences, Novartis Biomedical Research, Basel, Switzerland.
- Global Discovery Chemistry, Novartis Biomedical Research, Basel, Switzerland.
- Disease Area Oncology, Novartis Biomedical Research, Basel, Switzerland.
- Global Discovery Chemistry, Novartis Biomedical Research, Emeryville, CA, USA.
- Disease Area Immunology, Novartis Biomedical Research, Basel, Switzerland.
Zitieren
APA
Goretzki, B., Khoshouei, M., Schröder, M., Penner, P., Egger, L., Stephan, C., Argoti, D., Dierlamm, N., Rada, J. M., Kapps, S., Müller, C. S., Thiel, Z., Mutlu, M., Tschopp, C., Furkert, D., Freuler, F., Haenni, S., Tenaillon, L., Knapp, B., …, & Fernández, C. (2024). Dual BACH1 regulation by complementary SCF-type E3 ligases. Cell, 187(26), 7585-7602.e25. https://doi.org/10.1016/j.cell.2024.11.006
Vancouver
Goretzki B, Khoshouei M, Schröder M, Penner P, Egger L, Stephan C, et al. Dual BACH1 regulation by complementary SCF-type E3 ligases. Cell. 2024;187(26):7585-7602.e25. doi:10.1016/j.cell.2024.11.006
BibTeX
@article{Goretzki2024,
author = {Goretzki, Benedikt and Khoshouei, Maryam and Schröder, Martin and Penner, Patrick and Egger, Luca and Stephan, Christine and Argoti, Dayana and Dierlamm, Nele and Rada, Jimena Maria and Kapps, Sandra and Müller, Catrin Swantje and Thiel, Zacharias and Mutlu, Merve and Tschopp, Claude and Furkert, David and Freuler, Felix and Haenni, Simon and Tenaillon, Laurent and Knapp, Britta and Hinniger, Alexandra and Hoppe, Philipp and Schmidt, Enrico and Gutmann, Sascha and Iurlaro, Mario and Ryzhakov, Grigory and Fernández, César},
title = {Dual BACH1 regulation by complementary SCF-type E3 ligases},
journal = {Cell},
year = {2024},
volume = {187},
number = {26},
pages = {7585--7602.e25},
doi = {10.1016/j.cell.2024.11.006}
}
EUVIMED